For some TARGET cases, additional clinical data are missing, and OCG is currently working with the GDC to populate those fields. Some “Recurrent Blood Derived Cancer-Bone Marrow” samples are currently incorrectly identified and users should identify these samples as sample_type_id of “04” in both the aliquot barcode and in the GDC’s sample.sample_type_id field.
TARGET study associated RNA signatures of cytotoxic tumor-infiltrating lymphocytes with the presence of activated NK-/T-cells and suggested improved outcomes in newly diagnosed high-risk neuroblastoma patients with MYCN-NA tumor.
Authors identified transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma and showed that silencing TFAP4 inhibits MYCN-amplified neuroblastoma cell growth.
Scientists proposed a framework to investigate the genomic alterations in neuroblastoma subtypes and identified TEAD4, a transcription factor, as a novel target for therapy.
This study by TARGET researchers analyzed DNA changes and sequenced the genomes, exomes, and transcriptomes of 1,699 pediatric leukemia and solid tumors. Out of the 142 genes associated with cancer in these pediatric patients, only 45% matched those found in similar studies of adult cancers.